(16797697), S. L., (16797700), S. D. P., (16797703), L. E. O., (16375918), E. G., (16797706), J. P. B., (15135437), D. W., . . . (14940894), T. J. P. (2025). Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression.
শিকাগো স্টাইল (17 তম সংস্করণ) উদ্ধৃতি(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.
M.L.A (9 ম সংস্করণ) উদ্ধৃতি(16797697), Stephanie Lheureux, et al. Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression. 2025.